Refined Diagnostics

Executive Summary

Refined Diagnostics is a German medtech company specializing in compact, tunable ultrafast laser systems for label-free imaging and spectroscopy. Its core technology enables stimulated Raman scattering (SRS) microscopy, providing real-time molecular tissue analysis without exogenous contrast agents. This capability is particularly valuable in intraoperative settings, where rapid tumor margin assessment can reduce re-excision rates and improve patient outcomes. Founded in 2015, the company targets the gap between research-grade SRS systems and clinical adoption, aiming to deliver a device that integrates seamlessly into surgical workflows. The platform also holds potential for broader diagnostic applications in pathology and dermatology. The company has likely advanced its prototype through preclinical validation and is approaching clinical feasibility studies. Given the increasing interest in optical biopsy techniques and the demand for real-time diagnostics, Refined Diagnostics is well-positioned to address a significant unmet need. If successful, its laser systems could become standard tools in cancer surgery and beyond. However, the company remains privately held with no disclosed funding or revenue, suggesting it is in a development or early commercialization stage. The next 12–24 months will be critical for demonstrating clinical utility and securing regulatory clearance or partnerships.

Upcoming Catalysts (preview)

• Q2 2027Initiation of clinical trial for intraoperative SRS microscopy system70% success
• Q4 2026CE marking under EU Medical Device Regulation (MDR)60% success
• Q3 2026Strategic partnership with a surgical robotics or pathology company50% success